The effect of polyunsaturated phosphatidyl choline in the treatment of acute viral hepatitis

Aliment Pharmacol Ther. 1995 Dec;9(6):699-703. doi: 10.1111/j.1365-2036.1995.tb00441.x.

Abstract

Background: Polyunsaturated phosphatidyl choline is a preparation often advocated for diseases of the liver.

Methods: In a randomized open controlled trial, a preparation of polyunsaturated phosphatidyl choline, at a dose of 900 mg orally daily, was given to 22 patients with acute viral hepatitis. A control group of 25 patients was not treated.

Results: Serial serum bilirubin and alanine amino transferase levels were measured up to 12 weeks. The falls in their levels after 2 and 5 weeks, and the lengths of time to their normalization, were not significantly different in the treated group compared to the control group.

Conclusion: The results indicated that polyunsaturated phosphatidyl choline had no beneficial effect on the course of acute viral hepatitis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Alanine Transaminase / blood
  • Bilirubin / blood
  • Female
  • Hepatitis, Viral, Human / blood
  • Hepatitis, Viral, Human / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Phosphatidylcholines / therapeutic use*

Substances

  • Phosphatidylcholines
  • polyene phosphatidylcholine
  • Alanine Transaminase
  • Bilirubin